194 related articles for article (PubMed ID: 24916368)
21. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
22. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
23. The therapeutic role of Renin-Angiotensin System blockers in obesity- related renal disorders.
Santos SH; Simões e Silva AC
Curr Clin Pharmacol; 2014 Feb; 9(1):2-9. PubMed ID: 23270435
[TBL] [Abstract][Full Text] [Related]
24. [Antihypertensive drug therapy--combination of AT1-receptor blocker and betablocker].
Schindler C; Kosa M; Schröder J; Kirch W
Dtsch Med Wochenschr; 2010 May; 135(3):98. PubMed ID: 20077385
[No Abstract] [Full Text] [Related]
25. Renin-angiotensin system blocking drugs.
Robles NR; Cerezo I; Hernandez-Gallego R
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
[TBL] [Abstract][Full Text] [Related]
26. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
27. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
28. On target to dual block RAS?
Papadopoulos DP; Papademetriou V; Makris TK
Angiology; 2009 Dec-2010 Jan; 60(6):739-49. PubMed ID: 19144653
[TBL] [Abstract][Full Text] [Related]
29. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
Onuigbo MA
Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
[TBL] [Abstract][Full Text] [Related]
30. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
31. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
[TBL] [Abstract][Full Text] [Related]
32. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
33. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study.
van der Knaap R; Siemes C; Coebergh JW; van Duijn CM; Hofman A; Stricker BH
Cancer; 2008 Feb; 112(4):748-57. PubMed ID: 18181094
[TBL] [Abstract][Full Text] [Related]
34. Combination inhibition of the renin-angiotensin system: is more better?
Krause MW; Fonseca VA; Shah SV
Kidney Int; 2011 Aug; 80(3):245-55. PubMed ID: 21633407
[TBL] [Abstract][Full Text] [Related]
35. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
36. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
37. [Development and analyses of evaluation criteria for meta-analysis-relationship between renin-angiotensin system inhibitor and diabetes mellitus].
Iijima H; Osumi T; Koshimizu T
Yakugaku Zasshi; 2010 Sep; 130(9):1215-23. PubMed ID: 20823679
[TBL] [Abstract][Full Text] [Related]
38. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
39. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis.
Ishikane S; Takahashi-Yanaga F
Biochem Pharmacol; 2018 May; 151():96-103. PubMed ID: 29534876
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
Weinberger MH; Luft FC
Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
